{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T05:01:36Z","timestamp":1780722096510,"version":"3.54.1"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue des Maladies Respiratoires"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.rmr.2026.04.003","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T04:30:30Z","timestamp":1780720230000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Caract\u00e9ristiques des patients mucoviscidosiques avec VEMS stable sous trith\u00e9rapie ETI"],"prefix":"10.1016","author":[{"given":"N.","family":"Belard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Blin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Marchand","family":"Adam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Plantier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Th.","family":"Flament","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Mankikian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmr.2026.04.003_bib0125","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor\/tezacaftor\/ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3\u00a0trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.rmr.2026.04.003_bib0130","doi-asserted-by":"crossref","first-page":"104169","DOI":"10.1016\/j.lpm.2023.104169","article-title":"Cystic fibrosis","volume":"52","author":"Fajac","year":"2023","journal-title":"Presse Med"},{"key":"10.1016\/j.rmr.2026.04.003_bib0135","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.rmr.2015.11.010","article-title":"Nouvelles th\u00e9rapeutiques de la mucoviscidose ciblant le g\u00e8ne ou la prot\u00e9ine CFTR","volume":"33","author":"Hubert","year":"2016","journal-title":"Rev Mal Respir"},{"key":"10.1016\/j.rmr.2026.04.003_bib0140","unstructured":"pnds_affections_liees_ou_associees_a_cftr-vf.pdf n.d."},{"key":"10.1016\/j.rmr.2026.04.003_bib0145","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.3390\/cells11111769","article-title":"CFTR modulators in people with cystic fibrosis: real-world evidence in France","volume":"11","author":"Regard","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.rmr.2026.04.003_bib0150","doi-asserted-by":"crossref","first-page":"2300110","DOI":"10.1183\/13993003.00110-2023","article-title":"Theratyping cystic fibrosis patients to guide elexacaftor\/tezacaftor\/ivacaftor out-of-label prescription","volume":"62","author":"Dreano","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2026.04.003_bib0155","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(24)00208-X","article-title":"The expanded French compassionate programme for elexacaftor-tezacaftor-ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study","author":"Burgel","year":"2024","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.rmr.2026.04.003_bib0160","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor\u2013tezacaftor\u2013ivacaftor for cystic fibrosis with a single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2026.04.003_bib0165","first-page":"2","article-title":"Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist","volume":"9","author":"Nichols","year":"2023","journal-title":"J Clin Invest"},{"key":"10.1016\/j.rmr.2026.04.003_bib0170","doi-asserted-by":"crossref","first-page":"1275470","DOI":"10.3389\/fphar.2023.1275470","article-title":"Efficacy and safety profile of elexacaftor-tezacaftor-ivacaftor triple therapy on cystic fibrosis: a systematic review and single arm meta-analysis","volume":"14","author":"Xu","year":"2023","journal-title":"Front Pharmacol"},{"issue":"3","key":"10.1016\/j.rmr.2026.04.003_bib0175","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.chest.2024.03.033","article-title":"Relationship between lung volumes and heterogeneity in the response to elexacaftor\/tezacaftor\/ivacaftor in patients with cystic fibrosis and advanced lung disease","volume":"166","author":"Gramegna","year":"2024","journal-title":"CHEST"},{"key":"10.1016\/j.rmr.2026.04.003_bib0180","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jcf.2021.03.016","article-title":"Peripheral lung effect of elexacaftor\/tezacaftor\/ivacaftor in adult cystic fibrosis","volume":"21","author":"Stylemans","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.rmr.2026.04.003_bib0185","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1164\/rccm.200407-948OC","article-title":"Ventilation inhomogeneities in relation to standard lung function in patients with cystic fibrosis","volume":"171","author":"Kraemer","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.rmr.2026.04.003_bib0190","article-title":"The French Compassionate Program of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis with advanced lung disease and no F508del CFTR variant","volume":"61","author":"Burgel","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2026.04.003_bib0195","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1513\/AnnalsATS.202010-1336SD","article-title":"Evaluating the impact of stopping chronic therapies after modulator drug therapy in cystic fibrosis: the SIMPLIFY clinical trial study design","volume":"18","author":"Mayer-Hamblett","year":"2021","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.rmr.2026.04.003_bib0200","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1164\/rccm.202110-2249OC","article-title":"Effects of Elexacaftor\/Tezacaftor\/Ivacaftor therapy on CFTR function in patients with cystic fibrosis and one or two F508del Alleles","volume":"205","author":"Graeber","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2026.04.003_bib0205","unstructured":"KAFTRIO\/KALYDECO (KAFTRIO\u00a0: ivacaftor\/tezacaftor\/elexacaftor\/KALYDECO\u00a0: ivacaftor). Haute Autorit\u00e9 de sant\u00e9 n.d. https:\/\/www.has-sante.fr\/jcms\/p_3220388\/fr\/kaftrio-\/-kalydeco-kaftrio-ivacaftor-\/-tezacaftor-\/-elexacaftor\/-kalydeco-ivacaftor. (accessed January 14, 2025)."},{"key":"10.1016\/j.rmr.2026.04.003_bib0210","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.clnu.2023.12.017","article-title":"ESPEN-ESPGHAN-ECFS guidelines on nutrition care for cystic fibrosis","volume":"43","author":"Wilschanski","year":"2024","journal-title":"Clin Nutr"},{"issue":"Suppl.68","key":"10.1016\/j.rmr.2026.04.003_bib0215","article-title":"Limited effectiveness of elexacaftor-tezacaftor-ivacaftor on lung hyperinflation in adults with cystic fibrosis","volume":"64","author":"Dh\u00f4te","year":"2024","journal-title":"ERS Congress"},{"key":"10.1016\/j.rmr.2026.04.003_bib0220","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.amjmed.2008.04.005","article-title":"Primary care of the patient with chronic obstructive pulmonary disease-part 4: understanding the clinical manifestations of a progressive disease","volume":"121","author":"Cooper","year":"2008","journal-title":"Am J Med"},{"key":"10.1016\/j.rmr.2026.04.003_bib0225","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S2213-2600(21)00536-1","article-title":"The role of small airway dysfunction in asthma control and exacerbations: a longitudinal, observational analysis using data from the ATLANTIS study","volume":"10","author":"Kraft","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.rmr.2026.04.003_bib0230","unstructured":"Sweat chloride reflects CFTR function and correlates with clinical outcomes following CFTR modulator treatment\u00a0\u2013\u00a0ScienceDirect n.d. https:\/\/www-sciencedirect-com.proxy.scd.univ-tours.fr\/science\/article\/pii\/S156919932401854X. (accessed April 23, 2025)."},{"key":"10.1016\/j.rmr.2026.04.003_bib0235","doi-asserted-by":"crossref","first-page":"6114","DOI":"10.3390\/ijerph19106114","article-title":"Evaluating the effect of Kaftrio on perspectives of health and wellbeing in individuals with cystic fibrosis","volume":"19","author":"Aspinall","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.rmr.2026.04.003_bib0120","article-title":"Modulator-refractory cystic fibrosis: defining the scope and challenges of an emerging at-risk population","volume":"18","author":"Lindsay","year":"2024","journal-title":"Ther Adv Respir Dis"}],"container-title":["Revue des Maladies Respiratoires"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0761842526000112?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0761842526000112?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T04:30:40Z","timestamp":1780720240000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0761842526000112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":24,"alternative-id":["S0761842526000112"],"URL":"https:\/\/doi.org\/10.1016\/j.rmr.2026.04.003","relation":{},"ISSN":["0761-8425"],"issn-type":[{"value":"0761-8425","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Caract\u00e9ristiques des patients mucoviscidosiques avec VEMS stable sous trith\u00e9rapie ETI","name":"articletitle","label":"Article Title"},{"value":"Revue des Maladies Respiratoires","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmr.2026.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 SPLF. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}